Zobrazeno 1 - 8
of 8
pro vyhledávání: '"James S Welsh"'
Autor:
Don F. DeJongh, James S. Welsh, Mark Pankuch, Chelsea J. Miller, Caesar E. Ordoñez, John R. Winans, Basel Altoos, George Coutrakon, Ethan A. DeJongh, Nicholas T. Karonis, V. Rykalin
Publikováno v:
J Radiat Oncol
One of the major challenges to proton beam therapy at this time is the uncertainty of the true range of a clinical treatment proton beam as it traverses the various tissues and organs in a human body. This uncertainty necessitates the addition of gre
Autor:
Kristin J. Redmond, Indra J. Das, Chengcheng Gui, Jinyu Xue, Luke Peng, Howard Warren Goldman, Ting Martin Ma, Bahman Emami, Jimm Grimm, Rachelle Lanciano, S. Asbell, Lawrence Kleinberg, Luther W. Brady, James S. Welsh, Gregory J. Kubicek
Publikováno v:
Journal of Radiation Oncology. 8:53-61
Spinal cord dose constraints are a critical feature for stereotactic body radiation therapy (SBRT). Spinal cord maximum point dose (Dmax) by Monte Carlo (MC) calculations is used as a critical cord tolerance limit for SBRT, but information is lacking
Autor:
Kristin J. Redmond, Wolfram Laub, Indra J. Das, Harry Quon, Lawrence Kleinberg, Chengcheng Gui, Luther W. Brady, James S. Welsh, Bahman Emami, Nicholas Spoleti, Jinyu Xue, Gregory J. Kubicek, Rachelle Lanciano, S. Asbell, Jimm Grimm, L.C. Peng, Howard Warren Goldman
Publikováno v:
Journal of Radiation Oncology. 7:293-305
Stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), and stereotactic ablative body radiotherapy (SABR) are commonly used in the treatment of central nervous system (CNS) disease. This study has refined the radiation toxicity estim
Autor:
James S. Welsh, Don F. DeJongh, Caesar E. Ordoñez, Mark Pankuch, George Coutrakon, Ethan A. DeJongh, Nicole F Myers, Nicholas T. Karonis, Kirk L. Duffin, John R. Winans
Publikováno v:
J Radiat Oncol
OBJECTIVE: Proton beam therapy is an emerging modality for cancer treatment that, compared to X-ray radiation therapy, promises to provide better dose delivery to clinical targets with lower doses to normal tissues. Crucial to accurate treatment plan
Autor:
Kyle A Carey, Alec M. Block, Abhishek A. Solanki, Brendan Martin, Basel Altoos, Matthew M. Harkenrider, Mark Korpics, James S. Welsh
Publikováno v:
Journal of Radiation Oncology. 6:387-395
Most historic trials demonstrating the outcomes with bladder-preserving radiotherapy (RT) used 64–66 Gy. However, newer data suggest improved outcomes with dose escalation up to 70 Gy. Our objective was to explore the impact of dose escalation on o
Publikováno v:
Journal of Radiation Oncology. 6:109-115
Low-dose total body irradiation (LD-TBI) has been shown to be an effective therapy for patients with hematologic malignancies. The application of this method has fallen out of favor as newer systemic therapies have been developed. Nevertheless, for m
Publikováno v:
Journal of Radiation Oncology. 6:1-9
Publikováno v:
Journal of Radiation Oncology. 5:131-142
Melanoma has long been considered an “immunologic” malignancy because of numerous reports of spontaneous regression as well as abscopal phenomena along with its relative responsiveness to cancer immunotherapy. Over the past few years, there has b